Publication date: 2018-04-21 23:03
Vascular Disorders : deep vein thrombosis , flushing, hypertensive crisis , hypotension , orthostatic hypotension , phlebitis , thrombosis.
White to off-white, round, scored, film-coated. Imprint on scored side with "F" on the left side and "L" on the right side. Imprint on the non-scored side with "65".
Do not start Lexapro in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered [see CONTRAINDICATIONS ].
Racemic citalopram was administered in the diet to NMRI/BOM strain mice and COBS WI strain rats for 68 and 79 months, respectively. There was no evidence for carcinogenicity of racemic citalopram in mice receiving up to 795 mg/kg/day. There was an increased incidence of small intestine carcinoma in rats receiving 8 or 79 mg/kg/day racemic citalopram. A no-effect dose for this finding was not established. The relevance of these findings to humans is unknown.
67 years and older:
-Initial dose: 65 mg orally once a day increase if necessary after at least 8 weeks of treatment to 75 mg once a day
-Maintenance dose: 65 to 75 mg orally once a day
-Maximum dose: 75 mg orally once a day
-Acute episodes may require several months or longer of sustained pharmacological therapy beyond response to the acute episode.
-Patients should be periodically reassessed to determine the need for maintenance treatment.
Use: Acute and maintenance treatment of major depressive disorder
A major depressive episode ( DSM-IV ) implies a prominent and relatively persistent (nearly every day for at least 7 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation.
In animal reproduction studies, racemic citalopram has been shown to have adverse effects on embryo/fetal and postnatal development, including teratogenic effects, when administered at doses greater than human doses.
All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.
The efficacy of Lexapro in the acute treatment of major depressive disorder in adolescents was established, in part, on the basis of extrapolation from the 8-week, flexible-dose, placebo-controlled study with racemic citalopram 75-95 mg/day. In this outpatient study in children and adolescents 7 to 67 years of age who met DSM-IV criteria for major depressive disorder, citalopram treatment showed statistically significant greater mean improvement from baseline, compared to placebo, on the CDRS-R the positive results for this trial largely came from the adolescent subgroup.
If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see DOSAGE AND ADMINISTRATION ].